The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Perlecan heparan sulfate deficiency impairs pulmonary vascular development and attenuates hypoxic pulmonary hypertension.

På svenska

Author

  • Ya-Ting Chang
  • Chi-Nan Tseng
  • Philip Tannenberg
  • Linnéa Eriksson
  • Ke Yuan
  • Vinicio A de Jesus Perez
  • Johan Lundberg
  • Mariette Lengquist
  • Ileana Ruxandra Botusan
  • Sergiu-Bogdan Catrina
  • Phan-Kiet Tran
  • Ulf Hedin
  • Karin Tran Lundmark
Show all

Summary, in English

Excessive vascular cell proliferation is an important component of pulmonary hypertension (PH). Perlecan is the major heparan sulfate (HS) proteoglycan in the vascular extracellular matrix. It binds growth factors, including FGF2, and either restricts or promotes cell proliferation. In this study, we have explored the effects of perlecan HS deficiency on pulmonary vascular development and in hypoxia-induced PH.

Publishing year

2015

Language

English

Pages

20-31

Publication/Series

Cardiovascular Research

Volume

107

Issue

1

Document type

Journal article

Publisher

Oxford University Press

Topic

  • Cardiac and Cardiovascular Systems

Status

Published

Research group

  • Vessel Wall Biology

ISBN/ISSN/Other

  • ISSN: 1755-3245